Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Raised to “Hold” at Wall Street Zen

Posted by George Bondi on Nov 8th, 2026

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Several other equities analysts also recently commented on ARCT. Citigroup upgraded shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $8.00 to $20.00 in a report on Thursday, September 24th. Zacks Research raised shares of Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Thursday, October 15th. BTIG Research cut their target price on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 24th. Finally, Roth Capital reaffirmed a “buy” rating and set a $41.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.29.

Read Our Latest Stock Analysis on Arcturus Therapeutics

Arcturus Therapeutics Price Performance

Shares of ARCT stock opened at $10.35 on Friday. The stock has a market cap of $294.15 million, a P/E ratio of -3.36 and a beta of 2.62. The company has a fifty day moving average price of $13.10 and a two-hundred day moving average price of $9.05. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $17.96.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.43. Arcturus Therapeutics had a negative net margin of 285.92% and a negative return on equity of 45.35%. The company had revenue of $18.30 million for the quarter, compared to analyst estimates of $8.00 million. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -3.48 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. ACT Capital Partners L.P. acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth $308,000. Allspring Global Investments Holdings LLC boosted its position in shares of Arcturus Therapeutics by 4.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 28,782 shares of the biotechnology company’s stock valued at $394,000 after acquiring an additional 1,131 shares during the period. Alps Advisors Inc. boosted its position in shares of Arcturus Therapeutics by 29.6% in the third quarter. Alps Advisors Inc. now owns 37,390 shares of the biotechnology company’s stock valued at $512,000 after acquiring an additional 8,545 shares during the period. Green Alpha Advisors LLC grew its stake in shares of Arcturus Therapeutics by 7.9% in the third quarter. Green Alpha Advisors LLC now owns 29,234 shares of the biotechnology company’s stock valued at $400,000 after acquiring an additional 2,143 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of Arcturus Therapeutics by 648.6% in the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 2,627 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

(Get Free Report)

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.